Study S002433

Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease. A Randomized Control Trial.

ClinicalTrials.gov record

Registration

Registration: NCT07585526
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 160
Start: 2026-04-15
Primary completion: 2028-03-31
Lead sponsor: Institute of Liver and Biliary Sciences, India
Conditions: MASLD; Chronic Kidney Diseases
Interventions: DRUG:Finerenone; DRUG:Spironolactone; OTHER:Standard Medical Treatment
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Incidence of chronic kidney disease (CKD) in patients with MASLD/NAFLD related cirrhosis with clinical ascites at 6 months between both the groups, defined as: [6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.